Research programme: PPAR alpha agonists - CrystalGenomics

Drug Profile

Research programme: PPAR alpha agonists - CrystalGenomics

Alternative Names: PPAR alpha agonists - CrystalGenomics

Latest Information Update: 07 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CrystalGenomics
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 07 Feb 2011 Discontinued - Preclinical for Obesity in South Korea (unspecified route)
  • 28 May 2010 CrystalGenomics has merged with BexPharm
  • 07 Dec 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top